Nasdaq cprx.

Catalyst Pharmaceuticals, Inc. (CPRX) is a commercial-stage biopharmaceutical company that develops and commercializes therapies for patients with rare neuromuscular and neurological diseases.The company reported a solid second-quarter result, with total revenues growing 87.5% year-over-year to an all-time high of …Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton …Did Catalyst Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Catalyst Pharmaceuticals (NASDAQ: ...Per the terms of the agreement, CPRX is liable to make an upfront payment of $75 million to Santhera, along with a concurrent strategic equity investment of $15 million into Santhera.Find the latest Insider Activity data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.

Nov 14, 2022 · While the historical EPS growth rate for Catalyst is 42.6%, investors should actually focus on the projected growth. The company's EPS is expected to grow 92.3% this year, crushing the industry ...

Research Catalyst Pharmaceuticals' (Nasdaq:CPRX) stock key valuation metrics while comparing it with its industry peers & market side by side. Dashboard Markets Discover Watchlist Portfolios Screener. Catalyst Pharmaceuticals, Inc. ... What is CPRX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the ...Catalyst Pharmaceuticals - CPRX - Stock Price Today - Zacks Catalyst Pharmaceuticals (CPRX) (Delayed Data from NSDQ) $14.82 USD +0.39 (2.70%) Updated Dec 1, 2023 03:59 PM ET After-Market:...

While the historical EPS growth rate for Catalyst is 42.6%, investors should actually focus on the projected growth. The company's EPS is expected to grow 56% this year, crushing the industry ...Noteworthy ETF Inflows: XBI, BBIO, HALO, CPRX. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ...Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, engaged in the development and commercialization of therapies for rare debilitating ...Deerfield Management was the largest stakeholder in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the third quarter, holding 4.9 million shares worth $62.8 million. In total, 18 funds were long ...Noteworthy ETF Inflows: XBI, BBIO, HALO, CPRX. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ...

Dec 4, 2023 · Cetera Investment Advisers grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 7.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,223 shares of the biopharmaceutical company’s stock after acquiring an additional 1,096 shares during the quarter. Cetera […]

NASDAQ:CPRX. CUSIP N/A. CIK 1369568. Web www.catalystpharma.com. Phone (305) 420-3200. Fax 305-529-0933. Employees 82. Year Founded 2002. Price Target and Rating ...

Will Weakness in Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Prove Temporary Given Strong Fundamentals? (Simply Wall St.) Jul-19- ...The stock price of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has dropped by -10.68 compared to previous close of 13.44. Despite this, the company has seen a fall of -6.21% in its stock price over the last five trading days. GlobeNewsWire reported 2023-10-23 that The Company to Host a Conference CaCatalyst Pharmaceutical (CPRX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2022. This widely-known ...The latest price target for . Catalyst Pharmaceuticals (NASDAQ: CPRX) was reported by Cantor Fitzgerald on August 22, 2023.The analyst firm set a price target for $27.00 expecting CPRX to rise to ...https://www.catalystpharma.com. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of ...

Feb 27, 2023 · For the last reported quarter, Catalyst came out with earnings of $0.20 per share versus the Zacks Consensus Estimate of $0.19 per share, representing a surprise of 5.26%. For the previous quarter ... (NASDAQ: CPRX) Catalyst Pharmaceuticals currently has 106,582,857 outstanding shares. With Catalyst Pharmaceuticals stock trading at $12.85 per share, the total value of Catalyst Pharmaceuticals stock (market capitalization) is $1.37B .To wit, the Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) share price has soared 514% over five years. This just goes to show the value creation that some businesses can achieve.Based on 5 Wall Street analysts offering 12 month price targets for Catalyst Pharma in the last 3 months. The average price target is $23.30 with a high ...Right now, Catalyst has an S/TA ratio of 0.71, which means that the company gets $0.71 in sales for each dollar in assets. Comparing this to the industry average of 0.27, it can be said that the ...Its revenues for 2022 advanced over 2021 at an advanced 59% clip. During Catalyst's Q4, 2022 earnings call (the "Call") CEO McEnany forecast its 2023 revenues in a $245-$255 million range. Taking ...CPRX opened at $14.06 on Monday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $11.09 and a 52-week high of $22.11. The company has a 50 day moving average of $12.78 and a two-hundred day ...

Catalyst Pharmaceuticals last released its quarterly earnings data on November 8th, 2023. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). The business earned $102.69 million during the quarter, compared to the consensus estimate of $100.17 million.

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held ...10 hours ago · CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive ... Turning to the calls side of the option chain, the call contract at the $15.00 strike price has a current bid of $1.70. If an investor was to purchase shares of CPRX stock at the current price ...Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, engaged in the development and commercialization of therapies for rare debilitating ...There are 542 funds or institutions reporting positions in Catalyst Pharmaceuticals. This is an increase of 82 owner (s) or 17.83%. Average portfolio weight of all funds dedicated to US:CPRX is 0. ...Selling, general and administrative expenses totaled $14.7 million, up from $13.2 million reported in the year-ago quarter. As of Dec 31, 2022, CPRX had cash, cash equivalents and investments ...This value model looks for companies with high return on capital and earnings yields. CATALYST PHARMACEUTICALS INC ( CPRX) is a small-cap value stock in the Biotechnology & Drugs industry. The ...Analyst Future Growth Forecasts. Earnings vs Savings Rate: CPRX's forecast earnings growth (25.8% per year) is above the savings rate (2.2%). Earnings vs …

Based in Coral Gables, Florida, Catalyst Pharmaceuticals (NASDAQ:CPRX) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people ...

CPRX opened at $14.06 on Monday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $11.09 and a 52-week high of $22.11. The company has a 50 day moving average of $12.78 and a two-hundred day ...

(Nasdaq: CPRX) announced today that it has entered into definitive agreements to sell (i) 4.0 million shares of the Company's common stock, and (ii) common ...Jul 8, 2023 · This value model looks for companies with high return on capital and earnings yields. CATALYST PHARMACEUTICALS INC ( CPRX) is a small-cap value stock in the Biotechnology & Drugs industry. The ... Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, engaged in the development and commercialization of therapies for rare debilitating ...Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...January 24, 2023 — 12:26 pm EST. Written by Zacks Equity Research for Zacks ->. Shares of Catalyst Pharmaceuticals CPRX were down 29.0% on Jan 24 after management announced that it had received ...Find the latest SEC Filings data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Starbucks’ (NASDAQ:SBUX) 100% Return Could Be Coming At A Cost Dec 2, 2020 Tesla Inc., (NASDAQ:TSLA) is Getting Stronger, and it may be Time to Reevaluate Feb 11, 2022 Calculating The Fair Value ...CPRX Stock 12 Months Forecast. $23.30. (81.32% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Catalyst Pharma in the last 3 months. The average price target is $23.30 with a high forecast of $27.00 and a low forecast of $15.50. The average price target represents a 81.32% change from the last price of $12.85.Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms.

(NASDAQ: CPRX) Catalyst Pharmaceuticals currently has 106,582,857 outstanding shares. With Catalyst Pharmaceuticals stock trading at $12.85 per share, the total value of Catalyst Pharmaceuticals stock (market capitalization) is $1.37B .After-hours trades for Catalyst Pharmaceuticals Inc (CPRX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.26, or -1.94%, to $13.12. The Catalyst Pharmaceuticals Inc has recorded 366,653 volume in the after hours trading session.Aug 9, 2023 · CORAL GABLES, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “the Company”) (Nasdaq: CPRX) today reported financial results for the second quarter of 2023 and provided a corporate update. Catalyst Pharmaceuticals Inc share price live 13.860, this page displays NASDAQ CPRX stock exchange data. View the CPRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Catalyst Pharmaceuticals Inc real time stock price chart ...Instagram:https://instagram. dltnxman utd stock valuewhen to buy tesla stockcan i trade after hours on robinhood Catalyst Pharmaceutical (CPRX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ... the best vision insurance plansbest app to use for trading stocks Catalyst Pharmaceutical (CPRX) closed at $16.60 in the latest trading session, marking a -0.12% move from the prior day. This move was narrower than the S&P 500's daily loss of 0.7%.In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $16.44, marking a +1.99% move from the previous day. This change outpaced the S&P 500's 0.17% gain on the day. agnc stock forecast 2025 CPRX Catalyst Pharmaceuticals, Inc. Stock Price & Overview 17.97K followers $14.82 0.39 ( +2.70%) 4:00 PM 12/01/23 NASDAQ | $USD | Post-Market: $14.85 +0.03 (+0.20%) 7:59 PM Summary Ratings...Based on analysts offering 12 month price targets for CPRX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Its revenues for 2022 advanced over 2021 at an advanced 59% clip. During Catalyst's Q4, 2022 earnings call (the "Call") CEO McEnany forecast its 2023 revenues in a $245-$255 million range. Taking ...